Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 15, 2024
Abstract
Background:
While
there
exist
safe
hormonal
and
non-hormonal
therapeutic
interventions
for
the
menopause,
their
efficacy
profiles
are
not
fully
characterized.
To
use
a
symptom
checklist
to
examine
menopausal
relief
associated
with
different
treatments.
Methods:
An
online
survey
study
was
conducted
between
December
2023
February
2024.
Convenience
sampling
conducted,
participants
recruited
via
social
media,
email,
through
relevant
foundations
support
groups,
by
word-of-mouth.
Inclusion
criteria
were:
(1)
≥
18
years,
(2)
assigned
female
at
birth,
(3)
strong
comprehension
of
English
language,
(4)
must
be
currently
experiencing
symptoms
menopause
or
transition.
3330
respondents
consented
participate
in
these,
91.95%
(N
=
3062)
who
had
completed
least
88%
were
included
analysis.
Symptom
per
treatment
(transdermal
hormone
replacement
therapy
(HRT),
oral
HRT,
vaginal
antidepressants,
testosterone,
cognitive
behavioral
(CBT)/other
therapy/counseling)
assessed
using
Menopause-Specific
Quality
Life
(MENQOL)
questionnaire,
which
measures
four
domains:
vasomotor,
psychosocial,
physical,
sexual.
Results:
Data
from
total
3062
analysis
(mean
age
51.97,
SD
5.24).
Treatment
response
rates
differed
significantly
across
domains
(vasomotor:
F(5,2340)
204.93,
p
<
0.001,
η2
0.31;
psychosocial:
75.12,
0.14;
physical:
65.46,
0.12;
sexual:
89.34,
0.16).
Transdermal
HRT
performed
better
reducing
vasomotor
relative
all
other
options.
Regarding
psychosocial
symptoms,
CBT/other
therapy/counseling
outperformed
The
transdermal
testosterone
greater
physical
Finally,
higher
sexual
comparison
Conclusions:
findings
demonstrate
differential
treatments
domains,
underscoring
importance
comprehensive,
multidimensional
approach
management.
Utilizing
can
facilitate
tailoring
plans
specific
patient
needs.
outcomes
this
hold
considerable
implications
improving
shaping
guidelines
menopause.
Annals of Medicine,
Journal Year:
2024,
Volume and Issue:
56(1)
Published: Nov. 5, 2024
Background/Objectives
Chronic
pain
is
an
opioid
use
disorder
(OUD)
treatment
barrier
and
associated
with
poor
outcomes
in
OUD
including
relapse.
Fibromyalgia
a
chronic
condition
related
to
central
nervous
system
substrates
that
overlap
the
brain
disease
model
of
OUD.
We
know
no
studies
have
looked
at
non-treatment
seeking
individuals,
see
if
fibromyalgia
might
represent
treatment.
Given
many
non-treatment-seeking
individuals
previously
attempted
recovery
before
experiencing
relapse,
known
precipitant
be
currently
unappreciated
modifiable
factor
relapse
and,
potentially,
reengagement
among
those
not
This
study
aimed
determine
greater
odds
agreeing
'I
tried
stop
using
opioids
before,
but
caused
me
relapse'
